Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Cediranib in Recurrent Ovarian Cancer
NCT02345265Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and cediranib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival up to 32 months and Objective Response Rate up to 32 months. Started May 2016; status: active, not recruiting.
02
Drugs
olaparibcediranib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02345265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345265.